These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23925384)

  • 21. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of atazanavir in treatment-naive patients].
    Moreno S; Hernández B; Dronda F
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():90. PubMed ID: 15373065
    [No Abstract]   [Full Text] [Related]  

  • 24. A new protease inhibitor from Bristol-Myers Squibb.
    TreatmentUpdate; 2001; 12(12):5. PubMed ID: 11570092
    [No Abstract]   [Full Text] [Related]  

  • 25. Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
    Grant P; Taylor J; Cain P; Short W; Gallant J; Farthing C; Thal G; Coakley E; Zolopa A
    Clin Infect Dis; 2009 Mar; 48(5):680-2. PubMed ID: 19191657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
    Giuntini R; Martinelli C; Ricci E; Vichi F; Gianelli E; Madeddu G; Abeli C; Palvarini L; Penco G; Marconi P; Grosso C; Pellicano G; Bonfanti P; Quirino T
    HIV Med; 2010 Jan; 11(1):40-5. PubMed ID: 19686438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Report from the 13th retrovirus conference. Extending the role of atazanavir.
    Feinberg J
    AIDS Clin Care; 2006 Apr; 18(4):38. PubMed ID: 16718882
    [No Abstract]   [Full Text] [Related]  

  • 28. Atazanavir: a novel HIV-1 protease inhibitor.
    Piliero PJ
    Expert Opin Investig Drugs; 2002 Sep; 11(9):1295-301. PubMed ID: 12225250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
    TreatmentUpdate; 2009; 21(3):3-4. PubMed ID: 19623725
    [No Abstract]   [Full Text] [Related]  

  • 30. Reyataz monotherapy study stopped.
    Proj Inf Perspect; 2007 Oct; (44):23-4. PubMed ID: 18046835
    [No Abstract]   [Full Text] [Related]  

  • 31. Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.
    Poirier JM; Guiard-Schmid JB; Meynard JL; Bonnard P; Zouai O; Lukiana T; Jaillon P; Girard PM; Pialoux G
    AIDS; 2006 Apr; 20(7):1087-9. PubMed ID: 16603872
    [No Abstract]   [Full Text] [Related]  

  • 32. [Introduction. Usefulness of atazanavir in the treatment of patients infected by human immunodeficiency virus].
    Rivero A
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():1. PubMed ID: 20116609
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
    Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
    J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of atazanavir in rescue therapy].
    Portilla J; Boix V; Merino E; Reus S
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():22-7. PubMed ID: 20116613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
    Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Revised package insert for atazanavir.
    Sax PE
    AIDS Clin Care; 2008 Mar; 20(3):23. PubMed ID: 18399014
    [No Abstract]   [Full Text] [Related]  

  • 37. Atazanavir sulphate.
    Raja A; Lebbos J; Kirkpatrick P
    Nat Rev Drug Discov; 2003 Nov; 2(11):857-8. PubMed ID: 14702957
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-HIV agents. Atazanavir and saquinavir.
    TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
    [No Abstract]   [Full Text] [Related]  

  • 39. Electrocardiographic changes in HIV-infected, drug experienced patients treated with atazanavir.
    Mahnke L; Child M; Satin L; Persson A; Bertz R; Lawrence J
    AIDS; 2008 Aug; 22(13):1698. PubMed ID: 18670241
    [No Abstract]   [Full Text] [Related]  

  • 40. Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.
    Rekić D; Clewe O; Röshammar D; Flamholc L; Sönnerborg A; Ormaasen V; Gisslén M; Abelö A; Ashton M
    AAPS J; 2011 Dec; 13(4):598-605. PubMed ID: 21913053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.